Reducing bacterial transmission between mothers and infants
Impact of Bacterial Decolonization on Bacterial Burden Within Maternal-infant Dyads
NA · Duke University · NCT06541145
This study is testing whether a skin cleaning treatment for mothers before giving birth can reduce the spread of a certain bacteria to their infants.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Duke University (other) |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT06541145 on ClinicalTrials.gov |
What this trial studies
This study aims to measure the bacterial burden of Staphylococcus aureus and its transmission between mothers and their infants. Researchers will evaluate the effectiveness of a skin antisepsis treatment used by mothers prior to delivery and assess participant interest and compliance with this treatment. The study hypothesizes that increased maternal interest will lead to higher compliance rates. By understanding the dynamics of bacterial colonization and transmission, the study seeks to address the rising issue of antimicrobial resistance in maternal-infant dyads.
Who should consider this trial
Good fit: Ideal candidates for this study are mothers enrolled in the longitudinal Project HOPE1000 who are expecting infants.
Not a fit: Patients who are not enrolled in Project HOPE1000 will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the risk of bacterial infections in newborns by improving decolonization strategies for mothers.
How similar studies have performed: Other studies have shown success with similar decolonization approaches in high-risk patients, indicating potential for this method in maternal-infant dyads.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must be enrolled in longitudinal study Project HOPE1000. Exclusion Criteria: * Participants not enrolled in Project HOPE1000 will be excluded.
Where this trial is running
Durham, North Carolina
- Duke University — Durham, North Carolina, United States (RECRUITING)
Study contacts
- Principal investigator: Ibukunoluwa Kalu, MD — Duke University
- Study coordinator: Ibukunoluwa Kalu, MD
- Email: ica5@duke.edu
- Phone: (919) 684-6335
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Bacterial Colonization, Maternal, Infant, Neonatal, Resistant, Antimicrobial